New drug aims to stop the dizziness of standing up

NCT ID NCT07089043

Recruiting now Symptom relief Sponsor: CuraSen Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This study tests a new drug called CST-3056 in 12 adults with neurogenic orthostatic hypotension (a sharp drop in blood pressure when standing) caused by Parkinson's disease or pure autonomic failure. The goal is to see if the drug can improve blood pressure and reduce symptoms like dizziness. Participants will receive different doses to find the safest and most effective one.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROGENIC ORTHOSTATIC HYPOTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease primary orthostatic hypotension pure autonomic failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROGENIC ORTHOSTATIC HYPOTENSION

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

CuraSen Investigational Site
RECRUITING

Scottsdale, Arizona, 85251, United States

Contact
CuraSen Investigational Site
RECRUITING

Farmington Hills, Michigan, 48334, United States

Contact
CuraSen Investigational Site
RECRUITING

Eatontown, New Jersey, 07724, United States

Contact
CuraSen Investigational Site
RECRUITING

New York, New York, 10019, United States

Contact
CuraSen Investigational Site
RECRUITING

Nashville, Tennessee, 37240, United States

Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.